Protective effect of Vernonia amygdalina Delile against doxorubicin-induced cardiotoxicity
Vernonia amygdalina
Cardiotoxicity
DOI:
10.1016/j.heliyon.2021.e07434
Publication Date:
2021-06-29T15:50:48Z
AUTHORS (5)
ABSTRACT
Doxorubicin has been used as an anticancer drug and already indicated effective in the treatment of cancer. The incidence cardiotoxicity due to doxorubicin was approximately 11%, resulting limited use doxorubicin. Cardiac protection during therapy is needed because it can reduce heart failure. Vernonia amygdalina (VA) traditionally by Indonesians a traditional medicine contains many secondary metabolites, including vernolide, vernodalol, vernoamygdalin, vernolepin, luteolin, luteolin 7-O-beta-glucoronoside 7-O-glucoside. pharmacological activity VA widely studied, its antimalarial, antidiabetic, anticancer, hepatoprotective, nephroprotective, antioxidant activities. This research aimed determine 2,2-diphenyl-1-picrylhydrazyl (DPPH) scavenging activity, total phenol, flavonoid, cardioprotective effects Amygdalina. Negative control only intraperitoneal injection (20 mg/kgbw) on eight day while quercetin (85 ethanol extract (EEVA) 100, 200, 400 mg/kgbw dose are orally administered for consecutive days. Both EEVA groups were also injected with same day. On following day, rats ketamine HCL 75 dissected blood collected. collected 3 ml from each rat analyzed biochemical parameters. parameters Aspartate transaminase (AST), Alanine (ALT), Ureum, Creatinine, Creatinine kinase-MB (CK-MB), Lactate dehydrogenase (LDH), Troponin T, Brain natriuretic peptide (BNP), parameter Superoxide Dismutase (SOD). result showed that 40.51 ± 4.89 μg/mL, flavonoid 3.79 0.61 mg QE/g extract, phenol 281.575 1.069 GAE/g extract. Quercetin (400 AST, ALT, CK- MB, LDH, BNP significantly increase rats' SOD level compared negative control. So that, this study explicates potentials agent against reducing
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (49)
CITATIONS (23)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....